(S)-(+)-mecamylamine (TC-5214): a neuronal nicotinic receptor modulator enters phase III trials as an adjunct treatment for Major Depressive Disorder (MDD).
作者信息
Lindsley Craig W
出版信息
ACS Chem Neurosci. 2010 Aug 18;1(8):530-1. doi: 10.1021/cn100070s.
Abstract
摘要
相似文献
1
(S)-(+)-mecamylamine (TC-5214): a neuronal nicotinic receptor modulator enters phase III trials as an adjunct treatment for Major Depressive Disorder (MDD).
ACS Chem Neurosci. 2010 Aug 18;1(8):530-1. doi: 10.1021/cn100070s.
2
Efficacy and tolerability of flexibly-dosed adjunct TC-5214 (dexmecamylamine) in patients with major depressive disorder and inadequate response to prior antidepressant.
Eur Neuropsychopharmacol. 2014 Apr;24(4):564-74. doi: 10.1016/j.euroneuro.2013.12.008. Epub 2013 Dec 21.
3
Neuronal nicotinic receptor inhibition for treating mood disorders: preliminary controlled evidence with mecamylamine.
Depress Anxiety. 2002;16(3):89-92. doi: 10.1002/da.10035.
4
Two Phase III randomised double-blind studies of fixed-dose TC-5214 (dexmecamylamine) adjunct to ongoing antidepressant therapy in patients with major depressive disorder and an inadequate response to prior antidepressant therapy.
World J Biol Psychiatry. 2015 Oct;16(7):483-501. doi: 10.3109/15622975.2014.989261. Epub 2015 Jan 20.
5
Safety and tolerability of dexmecamylamine (TC-5214) adjunct to ongoing antidepressant therapy in patients with major depressive disorder and an inadequate response to antidepressant therapy: results of a long-term study.
J Clin Psychopharmacol. 2015 Feb;35(1):77-81. doi: 10.1097/JCP.0000000000000269.
6
Nicotinic antagonist augmentation of selective serotonin reuptake inhibitor-refractory major depressive disorder: a preliminary study.
J Clin Psychopharmacol. 2008 Jun;28(3):340-4. doi: 10.1097/JCP.0b013e318172b49e.
7
Nicotine, but not mecamylamine, enhances antidepressant-like effects of citalopram and reboxetine in the mouse forced swim and tail suspension tests.
Behav Brain Res. 2009 Jan 30;197(1):150-6. doi: 10.1016/j.bbr.2008.08.016. Epub 2008 Aug 22.
8
Similar activity of mecamylamine stereoisomers in vitro and in vivo.
Eur J Pharmacol. 2013 Nov 15;720(1-3):264-75. doi: 10.1016/j.ejphar.2013.10.018. Epub 2013 Oct 23.
9
Mecamylamine (Targacept).
IDrugs. 2006 Mar;9(3):205-17.
10
Nicotinic acetylcholine receptors as targets for antidepressants.
Mol Psychiatry. 2002;7(6):525-35. doi: 10.1038/sj.mp.4001035.
引用本文的文献
1
Towards new mechanisms: an update on therapeutics for treatment-resistant major depressive disorder.
Mol Psychiatry. 2015 Oct;20(10):1142-50. doi: 10.1038/mp.2015.92. Epub 2015 Jul 7.
2
Molecular interactions between mecamylamine enantiomers and the transmembrane domain of the human α4β2 nicotinic receptor.
Biochemistry. 2014 Feb 11;53(5):908-18. doi: 10.1021/bi400969x. Epub 2014 Jan 30.
3
Similar activity of mecamylamine stereoisomers in vitro and in vivo.
Eur J Pharmacol. 2013 Nov 15;720(1-3):264-75. doi: 10.1016/j.ejphar.2013.10.018. Epub 2013 Oct 23.
4
Citalopram versus other anti-depressive agents for depression.
Cochrane Database Syst Rev. 2012 Jul 11;2012(7):CD006534. doi: 10.1002/14651858.CD006534.pub2.
5
Translating laboratory discovery to the clinic: from nicotine and mecamylamine to Tourette's, depression, and beyond.
Physiol Behav. 2012 Dec 5;107(5):801-8. doi: 10.1016/j.physbeh.2012.06.023. Epub 2012 Jul 6.
6
Functional brain imaging of nicotinic effects on higher cognitive processes.
Biochem Pharmacol. 2011 Oct 15;82(8):943-51. doi: 10.1016/j.bcp.2011.06.008. Epub 2011 Jun 13.
本文引用的文献
1
The top prescription drugs of 2009 in the US: CNS therapeutics rank among highest grossing.
ACS Chem Neurosci. 2010 Jun 16;1(6):407-8. doi: 10.1021/cn1000556.
2
TC-5214 (S-(+)-mecamylamine): a neuronal nicotinic receptor modulator with antidepressant activity.
CNS Neurosci Ther. 2008 Winter;14(4):266-77. doi: 10.1111/j.1755-5949.2008.00054.x.
3
The economic burden of depression in the United States: how did it change between 1990 and 2000?
J Clin Psychiatry. 2003 Dec;64(12):1465-75. doi: 10.4088/jcp.v64n1211.
Zotero 插件